Singapore, March 5 -- Monash University has entered into a licensing agreement with CSL, marking a significant outcome that reflects the University's ambition and growing success in research translation and industry engagement. As Australia's largest biotechnology company, CSL plays a central role in the national life sciences ecosystem.

Under the agreement, CSL has in-licensed a Monash-originated antibody therapeutic programme focused on immune-mediated diseases, following a research collaboration established through CSL's external innovation efforts to accelerate scientific discoveries.

Immune-mediated diseases can occur when an immune response has an adverse effect on your body instead of, or in addition to, defending it.

The progra...